Ratings GoHealth, Inc.

Equities

GOCO

US38046W2044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
9.01 ^USD	-4.35%		-10.88%	-32.46%

May. 09	GoHealth, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Transcript : GoHealth, Inc., Q1 2024 Earnings Call, May 09, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Multiline Insurance & Brokers

	1st Jan change	Capi.	ESG Refinitiv
GOHEALTH, INC.	-32.46%	89.62M	D+
AON PLC	+0.71%	63.73B	C
ARTHUR J. GALLAGHER & CO.	+11.54%	54.81B	B-
WILLIS TOWERS WATSON PUBLIC LIMITED COMPANY	+6.52%	26.27B	C+
BROWN & BROWN, INC.	+22.44%	24.84B	C
CAIXA SEGURIDADE PARTICIPAÇÕES S.A.	+24.65%	9.36B	-
RYAN SPECIALTY HOLDINGS, INC.	+24.85%	6.39B	-
STEADFAST GROUP LIMITED	+1.20%	4.29B	B
AUB GROUP LIMITED	+13.59%	2.26B	C+
THE BALDWIN INSURANCE GROUP, INC.	+24.85%	1.98B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes